Fludara and B precursor type acute leukaemia - a phase IV clinical study of FDA data

Summary:

B precursor type acute leukaemia is reported as a side effect among people who take Fludara (fludarabine phosphate), especially for people who are female, 2-9 old, also take Ciclosporin, and have Bone marrow conditioning regimen.

The phase IV clinical study analyzes which people have B precursor type acute leukaemia when taking Fludara. It is created by eHealthMe based on reports of 46,669 people who have side effects when taking Fludara from the FDA, and is updated regularly.

What is Fludara?

Fludara has active ingredients of fludarabine phosphate. eHealthMe is studying from 46,686 Fludara users. Check the latest studies of Fludara.

What is B precursor type acute leukaemia?

B precursor type acute leukaemia (lymphoid cancer) is found to be associated with 31 drugs and 106 conditions by eHealthMe. Check the latest studies of B precursor type acute leukaemia.

On Jul, 06, 2026

46,669 people reported to have side effects when taking Fludara.
Among them, 17 people (0.04%) have B precursor type acute leukaemia.

Could Fludara cause B precursor type acute leukaemia?

Among these 17 people:

What is the gender of people who have B precursor type acute leukaemia when taking Fludara? *

female: 90 %
male: 10 %

What is the age of people who have B precursor type acute leukaemia when taking Fludara? *

What are other drugs people take besides Fludara? *

What are other side effects people have besides B precursor type acute leukaemia? *

Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 4 people, 23.53%
Thrombocytopenia (decrease of platelets in blood): 2 people, 11.76%
Fever: 2 people, 11.76%
Infection: 2 people, 11.76%
White Blood Cell Count Decreased: 1 person, 5.88%
Coagulation Test Abnormal: 1 person, 5.88%
Escherichia Infection (bacterial infection by escherichia coli): 1 person, 5.88%
Encephalopathy (functioning of the brain is affected by some agent or condition): 1 person, 5.88%
Death: 1 person, 5.88%
Cytomegalovirus Infection: 1 person, 5.88%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 3 people, 17.65%
Bone Marrow Conditioning Regimen: 3 people, 17.65%
Neuropathy Peripheral (surface nerve damage): 1 person, 5.88%
Metastases To Central Nervous System (cancer spreads to central nervous system): 1 person, 5.88%
Lymphocytic Leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes): 1 person, 5.88%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 5.88%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 1 person, 5.88%
Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Fludara and have B precursor type acute leukaemia?

- Check whether B precursor type acute leukaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fludara:

Fludara (46,686 reports)

Browse all side effects of Fludara:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with B precursor type acute leukaemia:

B precursor type acute leukaemia (31 drugs)

Browse all the conditions that are associated with B precursor type acute leukaemia:

B precursor type acute leukaemia (106 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fludarabine phosphate (the active ingredients of Fludara) and Fludara (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.